United States Nutraceutical Excipients Market Size & Outlook, 2025-2033
United States Nutraceutical Excipients Market Insights
- As highlighted in Deep Market Insights analysis, the United States Nutraceutical Excipients Market, worth USD 203.53 Million in 2024, is forecasted to achieve USD 363.46 Million by 2033.
- The United States market is anticipated to grow at a CAGR of 6.67% during the period 2026–2033.
- By 2024, Binders represented the largest share of the Excipient Type market size.
- Coatings is expected to remain the key growth driver within Excipient Type, registering the fastest CAGR during the forecast period.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, United States represented 26.11% of the overall global Nutraceutical Excipients Market size.
- United States is projected to lead the global Nutraceutical Excipients Market size by 2033.
- Across North America, United States is anticipated to hold the dominant position in market size by 2033.
- United States is forecasted to expand at the fastest pace in North America, attaining USD 363.92 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 203.53 Million |
| Market Size In 2033 | USD 363.46 Million |
| Largest segment | Binders |
| Units | Revenue in USD Million |
| CAGR | 6.67% (2025-2033) |
| Segmnetation Covered | |
| Excipient Type |
|
| Form |
|
| Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Nutraceutical Excipients Market Excipient Type 2025-2033 (USD Million)
| Excipient Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Binders | XX.x | XX.x | XX.x | 100.65 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fillers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Coatings | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Carriers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States Nutraceutical Excipients Market Form 2025-2033 (USD Million)
| Form | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Powder | XX.x | XX.x | XX.x | 99.28 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Granules | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pellets | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Liquid | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States Nutraceutical Excipients Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitamins | XX.x | XX.x | XX.x | 97.31 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Probiotics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Herbal supplements | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Functional blends | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.